Evidence for Expanding the Role of Streptomycin in the Management of Drug-Resistant Mycobacterium tuberculosis

In 2019, the WHO tuberculosis (TB) treatment guidelines were updated to recommend only limited use of streptomycin, in favor of newer agents or amikacin as the preferred aminoglycoside for drug-resistant Mycobacterium tuberculosis. However, the emergence of resistance to newer drugs, such as bedaqui...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Antimicrob Agents Chemother
Autors principals: Cohen, Keira A., Stott, Katharine E., Munsamy, Vanisha, Manson, Abigail L., Earl, Ashlee M., Pym, Alexander S.
Format: Artigo
Idioma:Inglês
Publicat: American Society for Microbiology 2020
Matèries:
Mechanisms of Resistance
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7449167/
https://ncbi.nlm.nih.gov/pubmed/32540971
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00860-20
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars